healthcare

Encompass Health declares $0.19 quarterly dividend payable July 15, 2026, demonstrating cash flow strength from its 175-hospital network.

$UNH rallied 36.9% in April on Q1 earnings beat and raised guidance, with improving medical loss ratios signaling healthcare cost recovery.

UnitedHealth deploys AI to recover from profit collapse caused by underestimated medical costs. Investors debate whether the turnaround strategy offers genuine opportunity or masks deeper challenges.

Abbott's dividend yield hits 10-year highs near 3%, leveraging 50+ consecutive dividend increases. Stock pricing reflects modest growth expectations amid cost pressures.

Abbott Laboratories ($ABT) slides 30% amid slower nutrition and diagnostics growth, but Dividend King status and $21B Exact Sciences deal attract value investors.

SBC Medical ($SBC) will release first-quarter 2026 earnings May 14, detailing performance across its diversified clinic portfolio amid U.S. and Asian expansion.

Psychemedics' 2026 report shows healthcare positive drug tests at 20.2%, transportation improves to 5.3%; cannabis most detected; hair testing offers superior detection.

Amazon launches GLP-1 weight management program through One Medical, leveraging its healthcare ecosystem and logistics capabilities to tap into a market projected to reach nearly $100 billion by 2030.

UnitedHealth rallied 30% on strong Q1 earnings and raised 2026 guidance, but current 19x forward earnings valuation may have priced in improvements. Medicare Advantage headwinds persist.

Swiss B2B BNPL market projected to grow 12.6% annually, reaching US$2.30 billion by 2030 from US$1.43 billion in 2026, driven by multi-sector adoption.

JATT II Acquisition Corp closed a $60M IPO on NASDAQ under ticker $JATT, priced at $10/share, focusing on healthcare and biotech combinations via data-driven discovery approaches.

NEXGEL accelerates shareholder update call to April 21 to discuss Celularity transaction, moving the conference forward by two days from original April 23 date.

AbbVie, Chevron, and Vici Properties offer yields of 3.3%, 3.8%, and 6.3% respectively, providing defensive income with proven 2022 downturn resilience.

CVS Health announces positive developments expected to boost revenue and profitability, receiving strong industry reception and signaling renewed investor confidence in the healthcare company.

Johnson & Johnson's 63-year dividend streak and AAA rating offer security, but 2.2% yield falls short of 4% income targets, requiring complementary holdings.

Questex and Fierce Sensors announce 2026 Best of Sensors Awards finalists spanning product innovation, MEMS, and IoT categories, recognizing leaders in sensor technology.

Three dividend stocks—Philip Morris, Pfizer, and UnitedHealth—offer compelling long-term value despite significant recent declines, supported by healthcare demographics and business transformation.

Analysis of Dow's three highest-yielding stocks—$VZ, $CVX, $UNH—reveals each faces significant headwinds despite attractive dividend payouts.

Johnson & Johnson maintains 63-year dividend growth streak, supported by strong pharmaceutical pipeline, $100B revenue projection, and AAA credit rating despite healthcare regulatory pressures.

U.S. stock market shifts toward value stocks in 2026. Vanguard Value ETF ($VTV) outperforms S&P 500 by 7 percentage points, driven by strength in financials and healthcare sectors.